# CJC-1295 (with DAC)

> Long-acting GHRH analog with a Drug Affinity Complex for albumin binding.

- Also known as: CJC-1295 DAC
- Class: Growth Hormone
- FDA approved: No
- Canonical page: https://www.americanpeptide.com/catalog/cjc-1295-with-dac

## Overview

Adds a maleimidopropionic acid (DAC) moiety to modified GRF(1-29), enabling covalent binding to serum albumin and extending half-life to roughly 6–8 days.

CJC-1295 with DAC adds a Drug Affinity Complex — a maleimidopropionic acid group — to Modified GRF(1-29), allowing the peptide to bind covalently to serum albumin. This extends its half-life to roughly 6–8 days, replacing the brief pulse of the no-DAC form with prolonged elevation.

The trade-off studied in the literature is physiologic: sustained GHRH-receptor exposure raises baseline GH and IGF-1 but blunts the natural pulsatility of the GH axis. It is a research compound and is not FDA-approved.

## Mechanism

GHRH receptor agonism with albumin-mediated extended exposure.

## Research areas

Studied in: Sustained GH release, IGF-1 elevation.

Guides on this site:

- [Growth Hormone & Body Composition](https://www.americanpeptide.com/research-areas/growth-hormone-axis): Secretagogues studied for GH release, IGF-1, and body composition.

## Key research

- Sustained exposure — albumin binding extends half-life to roughly 6–8 days (Teichman et al., 2006, J Clin Endocrinol Metab).
- GH / IGF-1 elevation — in early human study a single dose produced dose-dependent ~2–10-fold mean GH elevations and sustained IGF-1 increases lasting about 9–11 days.
- Pulsatility trade-off — continuous exposure raises baseline GH and IGF-1 but blunts the body’s natural pulsatile pattern.
- Compared to sermorelin / no-DAC — the same GHRH(1-29) backbone, but the DAC converts a minutes-long pulse into multi-day elevation.
- Not FDA-approved — research compound.

## FAQs

### What is CJC-1295 with DAC?

A long-acting GHRH analog whose Drug Affinity Complex binds albumin, extending its half-life to roughly a week for sustained GH and IGF-1 elevation.

### How does it differ from the no-DAC version?

The no-DAC form produces a brief GH pulse; the DAC form gives prolonged elevation by binding albumin, at the cost of natural pulsatility.

### What is a Drug Affinity Complex?

A chemical group that lets the peptide covalently attach to serum albumin, dramatically slowing its clearance.

### Is it approved?

No — it is a research compound. This page is a research and educational reference.

## Latest research

Recent trials and publications mentioning CJC-1295, pulled automatically from ClinicalTrials.gov and PubMed (unfiltered search results, refreshed daily).

### Recent trials

- [A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity](https://clinicaltrials.gov/study/NCT00267527) — TERMINATED · PHASE2 · NCT00267527

---

Source: AmericanPeptide.com — https://www.americanpeptide.com/catalog/cjc-1295-with-dac
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.